Fact checked byMindy Valcarcel, MS

Read more

June 24, 2023
1 min read
Save

Breast cancer specialist appointed senior VP of clinical research at Fred Hutch

Fact checked byMindy Valcarcel, MS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Sara A. Hurvitz, MD, has been appointed senior vice president of the clinical research division at Fred Hutchinson Cancer Center.

Hurvitz also will serve as head of the division of hematology and oncology within University of Washington’s department of medicine.

Graphic with headshot of/quote from Sara A. Hurvitz, MD

Her appointments will take effect Aug. 1.

“We believe [Hurvitz] is the right leader at the right time to bring together our hematology and oncology divisions, to build on our history of collaboration, accelerate research and advance education with the goal of improving care for our patients,” Thomas J. Lynch Jr., MD, president and director of Fred Hutch, said in a press release.

Hurvitz currently serves as associate professor at David Geffen School of Medicine at UCLA, medical director of Jonsson Comprehensive Cancer Center’s clinical research unit, and director of UCLA’s breast cancer clinical trials program.

Hurvitz started at UCLA as an intern and resident in 1999. She joined the faculty there in 2006.

She has extensive experience in translational research, with an emphasis on clinical trials.

“She is an internationally renowned clinical trialist but, equally important, she has a reputation of lifting up others around her,” Barbara Jung, MD, chair of the department of medicine at University of Washington, said in the release. “We know she will dedicate herself wholly to serving all members of this new division and build out the known strengths while embracing new opportunities.”

Hurvitz expects to play a key role in Fred Hutchinson’s effort to expand its clinical research pipeline, working to increase the institution’s reputation for solid tumor clinical research while overseeing growth of its research programs in cell therapy, stem cell transplantation, hematologic malignancies and nonmalignant hematology.

“Active listening is going to be a really key component for my first few years,” Hurvitz said in the release. “I’m not looking to disrupt any successes. I’m only looking to build on them.”